Apoptosis promoters

Details Apoptosis promoters Apoptosis promoters

2011-03-15

2011-03-15

Habte, Kahsay T (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C514S217050, C514S235500, C514S253040, C514S254010

Reexamination Certificate

active

07906505

ABSTRACT:
Compounds which inhibit the activity of anti-apoptotic family protein members, compositions containing the compounds and methods of treating diseases during which occur expression one or more than one of an anti-apoptotic family protein member are disclosed.

REFERENCES:
patent: 2413833 (1947-01-01), Kyrides
patent: 5138069 (1992-08-01), Carini et al.
patent: 6410584 (2002-06-01), Pamukcu et al.
patent: 6720338 (2004-04-01), Augeri et al.
patent: 7030115 (2006-04-01), Elmore et al.
patent: 7358251 (2008-04-01), Elmore et al.
patent: 7390799 (2008-06-01), Bruncko et al.
patent: 7449485 (2008-11-01), Elmore et al.
patent: 7504512 (2009-03-01), Augeri et al.
patent: 7585858 (2009-09-01), Elmore et al.
patent: 7642260 (2010-01-01), Bruncko et al.
patent: 7709467 (2010-05-01), Bruncko et al.
patent: 7767684 (2010-08-01), Bruncko et al.
patent: 2003/0119894 (2003-06-01), Murthy et al.
patent: 2003/0236247 (2003-12-01), Elmore et al.
patent: 2005/0159427 (2005-07-01), Bruncko et al.
patent: 2006/0128706 (2006-07-01), Bruncko et al.
patent: 2006/0258657 (2006-11-01), Bruncko et al.
patent: 2007/0072860 (2007-03-01), Bruncko et al.
patent: 2008/0076779 (2008-03-01), Elmore et al.
patent: 1685119 (2004-11-01), None
patent: 1685119 (2006-08-01), None
patent: 230136 (1991-12-01), None
patent: 200526559 (2004-11-01), None
patent: 200526559 (2005-08-01), None
patent: WO 02/24636 (2002-03-01), None
patent: WO 02/098848 (2002-12-01), None
patent: WO02098848 (2002-12-01), None
patent: WO 03/040107 (2003-05-01), None
patent: WO 03/080586 (2003-10-01), None
patent: WO 2004/043950 (2004-05-01), None
patent: WO 2004/048329 (2004-06-01), None
patent: WO 2005/049593 (2005-06-01), None
patent: WO 2005/049594 (2005-06-01), None
patent: WO2005049593 (2005-06-01), None
patent: WO2005049594 (2005-06-01), None
patent: WO 2008/017121 (2008-02-01), None
patent: WO 2008/017123 (2008-02-01), None
patent: WO2008017121 (2008-02-01), None
patent: WO2008017123 (2008-02-01), None
Amundson et al, “An Informatics Approach Identifying Markers of Chemosensitivity in Human Cancer Cell Lines,” Cancer Research, 60, 6101-6110 (2000).
Applicant's Amendment and Response dated Nov. 2, 2009, pp. 1-29, in response to U.S.P.T.O. Office Action for U.S. Appl. No. 11/127,940.
Applicant's Amendment and Response dated Nov. 19, 2009, pp. 1-6 in response to U.S.P.T.O. Office Action for U.S. Appl. No. 11/491,851.
Applicant's Amendment and Response dated Oct. 8, 2009, pp. 1-7, in response to U.S.P.T.O. Restriction Requirement for U.S. Appl. No. 11/600,445.
Banker, Gilbert S. et al., Modern Pharmaceuticals, 1996, Marcel Dekker, New York, pp. 596 and 451.
Cheng et al, “Synthesis of N-Heteroary1-7-azabicyclo[2.2.1]heptane Derivatives via Palladium-Bisimidazol-2-ylidene Complex Catalyzed Amination Reactions,” Organic Letters, 3(9), 1371-1374 (2001).
Corbett et al., “Discovery and preclinical antitumor efficacy evaluations of LY32262 and LY33169,” Investigational New Drugs, 2003, vol. 21:33-45.
Degterev, et al., “Identification of small-molecule inhibitors of interaction between the BH3 domain and Bcl-xL,” Nature Cell Biology, 2001, vol. 3, pp. 173-182.
Enyedy, et al., “Discovery of Small-Molecule Inhibitors of Bcl-2 through Structure-Based Computer Screening,” J. Med. Chem., 2001, 44, pp. 4313-4324.
Gambacorta, et al, “Bicyclo[3.3.1]nonane Approach to Triquinanes. Formal Synthesis of (+/−)Δ9(12)Campnellene and (+/−) Δ9 (12)Capnellene-8β-10α-diol,” Tetrahedron, 48(21), 4459-4464 (1992).
Holzelova, et al., “Autoimmune Lymphoproliferative Syndrome with Somatic Fas Mutations”, NEJM, 351, 1409-1418 (2004).
ISA, PCT International Preliminary Report on Patentability dated May 15, 2006, in International Application No. PCT/US2004/036770, filed Nov. 3, 2004.
ISA, PCT International Preliminary Report on Patentability dated May 15, 2006, in International Application No. PCT/US2004/037911, filed Nov. 12, 2004.
ISA, PCT International Search Report dated May 13, 2005, in International Application No. PCT/US2004/036770, filed Nov. 3, 2004.
ISA, PCT International Search Report dated May 13, 2005, in International Application No. PCT/US2004/037911, filed Nov. 12, 2004.
ISA, PCT International Search Report dated Mar. 22, 2007 for International Application No. PCT/US2006/018799.
ISA, Written Opinion for International Application No. PCT/US2006/018799, dated Mar. 22, 2007.
Oltersdorf, et al., “An inhibitor of Bcl-2 Family proteins induces regression of solid tumours”, Nature, 2005, 4 35, 677-681.
Petros, et al., “Solution structure of the antiapoptotic protein bcl-2”, PNAS, 98, 3012-3017.
Puck, et al., “Immune Disorders Caused by Defects in the Caspase Cascade”, Current Allergy and Asthma Reports, 3, 378-384 (2003).
Rengan, et al-, “Actin cytoskeletal function is spared, but apoptosis is increased, in WAS patient Hematopoietic cells”, Blood, 95(4), 1283-1292 (2000).
Sattler, et al., “Structure of Bcl-xL-Bak Peptide Complex: Recognition Between Regulators of Apoptosis”, Science, 275, 983-986 (1997).
Shimazaki, et al., “Evaluation of apoptosis as a prognostic factor in myelodysplastic syndromes”, British J Haematology, 110(3), 584-590 (2000).
Tse et al., “ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor,” Cancer Research May 1, 2008, 68(9):3421-3428.
U.S.P.T.O., Office Action/Restriction Requirement dated Apr. 25, 2008, cover sheet and pp. 1-7, for U.S. Appl. No. 11/127,940.
U.S.P.T.O. Non-Final Office Action dated Sep. 12, 2008 in U.S. Appl. No. 11/202,827.
U.S.P.T.O., Non-final Office Action dated Nov. 28, 2008 in U.S. Appl. No. 12/120,914.
U.S.P.T.O., Notice of Allowance and Fee(s) Due, dated Jul. 1, 2009, p. 1, for U.S. Appl. No. 11/202,827.
U.S.P.T.O., Notice of Allowability, dated Jul. 1, 2009, p. 1-2, for U.S. Appl. No. 11/202,827.
U.S.P.T.O., Interview Summary, dated Jul. 1, 2009, p. 1, for U.S. Appl. No. 11/202,827.
U.S.P.T.O., Examiner's Amendment, dated Jul. 1, 2009, pp. 2-4, for U.S. Appl. No. 11/202,827.
U.S.P.T.O., Final Office Action dated Aug. 12, 2009 in U.S. Appl. No. 12/120,914.
Wang, et al., “Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells,” PNAS, Jun. 20, 2000, vol. 97, No. 13, pp. 7124-7129.
Wang, et al., “A novel small molecule inhibitor of Bcl-XLinhibits tumor growth in a human head and neck squamous cell carcinoma xenograft model,” Proceedings of the American Association for Cancer Research, Jul. 2003, vol. 44, 2ndEd., p. 942, #4740 Abstract.
Wang, et al., “An Efficient Synthesis of ABT-263, a Novel Inhibition of Anti-apoptotic Bcl-2 Proteins,” Synthesis, 2008, 15, 2398-2404.
Wolff, Manfred E., Burger's Medicinal Chemistry and Drug Discovery, Fifth Ed. vol. 1: Principles and Practice, John Wiley & Sons, 1995, pp. 975-977.
Zhang, et al., “Development of a high-throughput fluorescence polarization assay for Bcl-xL”, Analytical Biochemistry, 307, 70-75 (2002).
Amundson et al., “An Informatics Approach Identifying Markers of Chemosensitivity in Human Cancer Cell Lines,” Cancer Research, 2000, 60, pp. 6101-6110.
Applicant's Amendment and Response dated Nov. 19, 2009, pp. 1-6 in response to U.S.P.T.O. Office Action for U.S. Appl. No. 11/491,851.
Applicant's Amendment and Response dated Nov. 2, 2009, pp. 1-29, in response to U.S.P.T.O. Office Action for U.S. Appl. No. 11/127,940.
Applicant's Amendment and Response dated Oct. 8, 2009, pp. 1-7, in response to U.S.P.T.O. Restriction Requirement for U.S. Appl. No. 11/600,445.
Cheng, et al., “Synthesis of N-Heteroaryl-7-azabicyclo[2.2.1]heptane Derivatives via Palladium-Bisimidazol-2-ylidene Complex Catalyzed Amination Reactions,” Organic Letters, 2001, 3—Issue 9, pp. 1371-1374.
Gambacorta et al., “Bicyclo[3.3.1]nonane Approach to Triquinanes. Formal Synthesis of (+/−)9(12)Campnellene

Affiliated with

Also associated with

Rating

Apoptosis promoters does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Apoptosis promoters, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Apoptosis promoters will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2644912